Amgen Inc. has received  the Food and Drug Administration approved updated safety information, including an updated boxed label warning that certain anemia drugs like Amgen's Aranesp and Epogen shorten overall survival or time-to-tumor progression in some cancer patients. Amgen said it is informing health-care professionals about revisions to the U.S. prescribing information and it is informing health-care professionals about revisions to the U.S. prescribing information.